Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.
Prostatic acid phosphatase (PAP) is one of the prostate-related antigens that are applicable to specific immunotherapy for patients with prostate cancer. In this study, we determined whether or not PAP could be a target molecule in specific immunotherapy for patients with nonprostate cancer. A variety of adenocarcinoma cell lines were examined for their PAP expression at the mRNA and protein levels by reverse transcription polymerase chain reaction and western blot analysis, respectively. Considerable percentages of colon, gastric, and breast cancer cell lines were found to be positive for PAP at both the mRNA and the protein levels. The PAP expression in cancer tissues was also confirmed by immunohistochemical staining. In addition, we examined whether cancer-reactive cytotoxic T lymphocytes (CTLs) could be induced from peripheral blood mononuclear cells (PBMCs) of human leukocyte antigen (HLA) A24+ nonprostate cancer patients by in vitro stimulation with a PAP peptide. As a result, tumor-specific CTLs could be induced from the PBMCs of HLA-A24+ colon and gastric cancer patients. Their cytotoxicity against HLA-A24+ cancer cells was dependent on PAP peptide-specific and CD8+ T cells. These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.
Wang
Yi
Y
Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan.
Harada
Mamoru
M
Yano
Hirohisa
H
Ogasawara
Sachiko
S
Takedatsu
Hiroko
H
Arima
Yoshimi
Y
Matsueda
Satoko
S
Yamada
Akira
A
Itoh
Kyogo
K
D000135:Acid Phosphatase; D000230:Adenocarcinoma / Q000097:blood / Q000201:enzymology* / Q000235:genetics; D001943:Breast Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics; D045744:Cell Line, Tumor / Q000201:enzymology* / Q000276:immunology; D003110:Colonic Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics; D005260:Female; D005753:Gastric Mucosa / Q000201:enzymology; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D015234:HLA-A Antigens / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D010455:Peptides / Q000494:pharmacology; D017027:Protein Tyrosine Phosphatases / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D010455:Peptides; D012333:RNA, Messenger; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases